NOS3 and neoplasm: In conclusion, we demonstrated that eNOS-siRNA loaded into MBs and released by US is an efficient and safe non-viral nucleic acid transfection strategy with improved cellular specificity, thereby showing potential as anti-angiogenic therapeutic agent to improve tumor control.